Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBP431
- Development stage
- Unknown
- Lead developer
- Mapp Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MBP431 is an experimental monoclonal antibody cocktail developed by MAPP Biopharmaceuticals specifically for the treatment of Ebola virus disease caused by the Sudan virus (SUDV). The cocktail is composed of two potent, neutralizing human monoclonal antibodies, mAb282 and mAb322, which were originally identified from survivors of Sudan virus infections. These antibodies target non-overlapping epitopes on the Sudan virus glycoprotein (GP), working synergistically to neutralize the virus and block its entry into host cells. Developed with significant support from the Biomedical Advanced Research and Development Authority (BARDA), MBP431 has undergone Phase 1 clinical evaluation and was deployed for compassionate use during the 2022 Sudan virus outbreak in Uganda.
- Other names
- Sudan virus monoclonal antibody cocktailSUDV mAb cocktailSudan ebolavirus mAb cocktail
02
Targets
Zaire ebolavirus glycoproteinBDBV GP (Bundibugyo ebolavirus glycoprotein)
Beyond the preview
Go deeper on MBP431.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBP431.